A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

June 22, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
BIOLOGICAL

RSVpreF 120 µg

RSVpreF standard dose level

BIOLOGICAL

RSVpreF 60 µg

RSVpreF low dose level

Trial Locations (17)

14609

Rochester Clinical Research, LLC, Rochester

27703

Duke Vaccine And Trials Unit, Durham

33144

Bio-Medical Research LLC, Miami

35233

University of Alabama at Birmingham - School of Medicine, Birmingham

44121

Senders Pediatrics, South Euclid

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

51106

Velocity Clinical Research, Sioux City, Sioux City

68134

Velocity Clinical Research, Omaha, Omaha

70006

Velocity Clinical Research, New Orleans, Metairie

78726

Innovo Research - Austin Regional Clinic, Austin

78759

Velocity Clinical Research, Austin, Austin

84088

Velocity Clinical Research, Salt Lake City, West Jordan

90274

Peninsula Research Associates, Rolling Hills Estates

94304

Stanford University Medical Center, Palo Alto

98101

Seattle Children's - Building Cure, Seattle

98105

Seattle Children's Hospital, Seattle

02818

Velocity Clinical Research, Providence, East Greenwich

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY